MedTrace Logo

Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment

NCT04765644 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-04-17

Study results available
· View outcomes & findings →

Summary

A single centre, placebo controlled, blinded (participant, investigator, outcome assessor) trial to evaluate the effects of COX-2 inhibition with celecoxib on endothelial function in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

Celecoxib

Two 200 mg capsules per day (400 mg/day) for 7 days

OTHER

Placebo

2 capsules/day for 7 days

OTHER

L-arginine + placebo

L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days

OTHER

L-arginine + celecoxib

L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Jane Mitchell, Professor · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2022-01-24
Completion
2022-01-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04765644 on ClinicalTrials.gov